Literature DB >> 24192813

Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients.

C H Kok1, T Leclercq2, D B Watkins1, V Saunders2, J Wang1, T P Hughes3, D L White4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24192813     DOI： 10.1038/leu.2013.329

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  A nuclear protein tyrosine phosphatase TC-PTP is a potential negative regulator of the PRL-mediated signaling pathway: dephosphorylation and deactivation of signal transducer and activator of transcription 5a and 5b by TC-PTP in nucleus.

Authors:  Naohito Aoki; Tsukasa Matsuda
Journal:  Mol Endocrinol       Date:  2002-01

2.  "Stemness": transcriptional profiling of embryonic and adult stem cells.

Authors:  Miguel Ramalho-Santos; Soonsang Yoon; Yumi Matsuzaki; Richard C Mulligan; Douglas A Melton
Journal:  Science       Date:  2002-09-12       Impact factor: 47.728

3.  ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments.

Authors:  Alexander Lachmann; Huilei Xu; Jayanth Krishnan; Seth I Berger; Amin R Mazloom; Avi Ma'ayan
Journal:  Bioinformatics       Date:  2010-08-13       Impact factor: 6.937

4.  Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation.

Authors:  C H Kok; D B Watkins; T Leclercq; R J D'Andrea; T P Hughes; D L White
Journal:  Leukemia       Date:  2013-02-15       Impact factor: 11.528

5.  Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML.

Authors:  Florian H Heidel; Lars Bullinger; Zhaohui Feng; Zhu Wang; Tobias A Neff; Lauren Stein; Demetrios Kalaitzidis; Steven W Lane; Scott A Armstrong
Journal:  Cell Stem Cell       Date:  2012-04-06       Impact factor: 24.633

6.  Identification of a nuclear Stat1 protein tyrosine phosphatase.

Authors:  Johanna ten Hoeve; Maria de Jesus Ibarra-Sanchez; Yubin Fu; Wei Zhu; Michel Tremblay; Michael David; Ke Shuai
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

7.  Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.

Authors:  Luana Casetti; Séverine Martin-Lannerée; Imen Najjar; Isabelle Plo; Sylvie Augé; Lydia Roy; Jean-Claude Chomel; Evelyne Lauret; Ali G Turhan; Isabelle Dusanter-Fourt
Journal:  Cancer Res       Date:  2013-02-11       Impact factor: 12.701

8.  The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl.

Authors:  Aninda Mitra; Kotagiri Sasikumar; B V V Parthasaradhi; Vegesna Radha
Journal:  Biochim Biophys Acta       Date:  2012-10-31

9.  STAT5 signaling is required for the efficient induction and maintenance of CML in mice.

Authors:  Dan Ye; Nicholas Wolff; Li Li; Shumin Zhang; Robert L Ilaria
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

10.  Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia.

Authors:  Stephany Corrêa; Renata Binato; Bárbara Du Rocher; Morgana T L Castelo-Branco; Luciana Pizzatti; Eliana Abdelhay
Journal:  BMC Cancer       Date:  2012-07-23       Impact factor: 4.430
View more
  5 in total

1.  Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib.

Authors:  Chung H Kok; David T Yeung; Liu Lu; Dale B Watkins; Tamara M Leclercq; Phuong Dang; Verity A Saunders; John Reynolds; Deborah L White; Timothy P Hughes
Journal:  Blood Adv       Date:  2019-05-28

2.  PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells.

Authors:  Julia Drube; Thomas Ernst; Markus Pfirrmann; Benadict Vincent Albert; Sebastian Drube; Daniela Reich; Anne Kresinsky; Kathrin Halfter; Claudio Sorio; Christian Fabisch; Andreas Hochhaus; Frank-D Böhmer
Journal:  Oncotarget       Date:  2018-01-15

3.  Inhibition of protein tyrosine phosphatase non-receptor type 2 by PTP inhibitor XIX: Its role as a multiphosphatase inhibitor.

Authors:  Hien Thi Thu Le; Young-Chang Cho; Sayeon Cho
Journal:  BMB Rep       Date:  2017-06       Impact factor: 4.778

4.  Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.

Authors:  Georgios Nteliopoulos; Alexandra Bazeos; Simone Claudiani; Gareth Gerrard; Edward Curry; Richard Szydlo; Mary Alikian; Hui En Foong; Zacharoula Nikolakopoulou; Sandra Loaiza; Jamshid S Khorashad; Dragana Milojkovic; Danilo Perrotti; Robert Peter Gale; Letizia Foroni; Jane F Apperley
Journal:  Haematologica       Date:  2019-05-09       Impact factor: 9.941

5.  Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.

Authors:  Peng-Fei Wang; Hong-Qing Cai; Chuan-Bao Zhang; Yan-Michael Li; Xiang Liu; Jing-Hai Wan; Tao Jiang; Shou-Wei Li; Chang-Xiang Yan
Journal:  J Neuroinflammation       Date:  2018-05-15       Impact factor: 8.322
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.